SCHEDULE: FMR LLC Reports 5.1% Stake in Edgewise Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 5.1% of Edgewise Therapeutics' common stock as of June 30, 2026.

Summary

• FMR LLC, through its subsidiaries and affiliates, along with Abigail P. Johnson, has reported beneficial ownership of 5,489,135 shares of Edgewise Therapeutics Inc. common stock.
• This ownership stake represents 5.1% of the class of securities.
• The filing is a Schedule 13G, indicating passive investment by FMR LLC.
• The reporting date for this ownership is June 30, 2026.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.

Positives

• FMR LLC's investment indicates confidence in Edgewise Therapeutics' long-term prospects, as it is a significant institutional investor.
• The passive nature of the filing (Schedule 13G) suggests FMR LLC is not seeking to control the company, which can be viewed positively by existing management and shareholders.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Edgewise Therapeutics, limiting its immediate impact on valuation.
• The significant ownership by FMR LLC could be perceived as a potential future catalyst for a change in control or strategy, which may or may not be beneficial to all stakeholders.

Risks

• As a Schedule 13G filing, it indicates a passive investment. However, significant ownership by large institutional investors can sometimes precede activist campaigns or strategic shifts, introducing uncertainty.
• The filing does not contain forward-looking statements or risk factors specific to Edgewise Therapeutics' business operations, only reporting ownership.

Future Outlook

This filing is a Schedule 13G, which reports passive beneficial ownership. It does not contain forward-looking statements or guidance regarding Edgewise Therapeutics' future financial performance or strategic direction.

Management Comments

• FMR LLC and Abigail P. Johnson, through their respective filings and powers of attorney, certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional investment, as reported in this Schedule 13G by FMR LLC, is a common indicator of a company's perceived stability and growth potential within the biotechnology sector. However, the passive nature of this filing suggests FMR LLC is currently a portfolio holder rather than an active participant in strategic decisions.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC may influence market perception and potentially attract further institutional interest. The passive nature of the investment is generally viewed neutrally.
• Management: The filing confirms FMR LLC's passive investment, which typically does not directly impact current management's operational control unless a shift to an active stake occurs.
• Creditors/Suppliers: No direct impact is indicated by this ownership filing.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership of Edgewise Therapeutics' common stock.
• Future filings will be made if there are material changes in beneficial ownership or if the investment strategy shifts from passive to active.

Key Dates

Keywords

Edgewise Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment